Immunemodulation in Patients With Minor Head Injury - Full Text View

Immunemodulation in Patients With Minor Head Injury (MHI)

This study is currently recruiting participants.

Verified by Medical University of Vienna, February 2008

Sponsored by:	Medical University of Vienna
Information provided by:	Medical University of Vienna
ClinicalTrials.gov Identifier:	NCT00622778

Purpose

The purpose of this study is to try to prove the worth of the two (2) Serum Proteins S-100 Beta and NSE in combination with a diagostic algorithm to help to establish diagnosis in patients with minor head injury.

Condition
Head Trauma

MedlinePlus related topics: Injuries Traumatic Brain Injury Wounds

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Diagnostic Algorithm in Minor Head Injury

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:

Intracranial Haematoma [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

Serum from peripheral blood

Estimated Enrollment:	130
Study Start Date:	October 2007
Estimated Study Completion Date:	July 2008
Estimated Primary Completion Date:	May 2008 (Final data collection date for primary outcome measure)

Groups/Cohorts
1 Patients from daily practice

Eligibility

Ages Eligible for Study:	1 Year and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients from daily practice

Criteria

Inclusion Criteria:

minor head injury

Exclusion Criteria:

severe head injury

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00622778

Contacts

Contact: Harald Wolf, M.D.	+43-1-40400 ext 5959	Harald.Wolf@meduniwien.ac.at
Contact: Kambiz Sarahrudi, M.D.	+43-1-40400 ext 5959	Kambiz.Sarahrudi@meduniwien.ac.at

Locations

Austria
Medical University of Vienna	Recruiting
Vienna, Austria, 1090
Contact: Harald Wolf, M.D. +43-1-40400 ext 5959 Harald.Wolf@meduniwien.ac.at

Sponsors and Collaborators

Medical University of Vienna

Investigators

Study Chair:

Vilmos Vecsei, M.D. Professor

Head of Department

More Information

Publications:

Pelinka LE, Toegel E, Mauritz W, Redl H. Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock. 2003 Mar;19(3):195-200.

Pelinka LE, Bahrami S, Szalay L, Umar F, Redl H. Hemorrhagic shock induces an S 100 B increase associated with shock severity. Shock. 2003 May;19(5):422-6.

Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma. 2004 Nov;21(11):1553-61.

Responsible Party:	Department for Trauma Surgery ( Dr. Harald Wolf )
Study ID Numbers:	3
Study First Received:	February 13, 2008
Last Updated:	February 13, 2008
ClinicalTrials.gov Identifier:	NCT00622778
Health Authority:	Austria: Medical University of Vienna local Ethics Committee

Keywords provided by Medical University of Vienna:

intracranial bleeding
computed tomography scan

Study placed in the following topic categories:

Craniocerebral Trauma
Wounds and Injuries
Disorders of Environmental Origin

Trauma, Nervous System
Intracranial Hemorrhages
Hemorrhage

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009